Remogliflozin etabonate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Remogliflozin etabonate
Remogliflozin etabonate structure.svg
Systematic (IUPAC) name
5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Clinical data
Legal status ?
Routes Oral
Identifiers
CAS number 442201-24-3 YesY
ATC code None
UNII TR0QT6QSUL N
KEGG D10055 N
ChEMBL CHEMBL494323 N
Chemical data
Formula C26H38N2O9 
Mol. mass 522.586 g/mol
 N (what is this?)  (verify)

Remogliflozin etabonate (INN/USAN)[1] is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline.[2] Remogliflozin is now being developed by BHV Pharma.[citation needed]

Method of action[edit]

Remogliflozin inhibits the sodium-glucose transport proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]

See also[edit]

References[edit]

  1. ^ Statement on a nonproprietory name adopted by the USAN council
  2. ^ Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M (June 2008). "Remogliflozin etabonate, in a Novel Category of Selective Low-Affinity / High-Capacity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models". J. Pharmacol. Exp. Ther. 327 (1): 268–276. doi:10.1124/jpet.108.140210. PMID 18583547. 
  3. ^ Prous Science: Molecule of the Month November 2007